Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Protalix is a development-stage biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The Company's lead product candidate is prGCD for the treatment of Gaucher disease, which is currently in a pivotal Phase III clinical trial. The Company has no approved products and has not generated significant product revenue since a contract expired in 2005.
Key Financial Metrics
| Metric (in thousands, except per share) | Three Months Ended Mar 31, 2008 | Three Months Ended Mar 31, 2007 |
|---|---|---|
| Revenues | $830 | $0 |
| Net Loss | $(5,113) | $(3,450) |
| Net Loss Per Share (Basic & Diluted) | $(0.07) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $57,782 | $24,896 |
| Net Cash Used in Operating Activities | $(3,807) | $(2,856) |
| Net Cash Used in Investing Activities | $(856) | $(534) |
| Net Cash Provided by Financing Activities | $(17) | $12,871 |
| Total Assets | $65,826 | $68,137 (Dec 31, 2007) |
| Total Liabilities | $5,077 | $4,452 (Dec 31, 2007) |
Note: The filing does not provide a specific gross margin percentage, though Gross Profit for the quarter was $624,000 against $830,000 in revenue.
Material Changes vs. Prior Period
- Revenue: The Company recognized $830,000 in revenue, primarily from a prior R&D services contract that expired in 2005. This represents a nominal increase from the prior year quarter which had no revenue.
- Net Loss: Net loss increased by approximately 48% to $5.1 million from $3.5 million in the prior year quarter.
- Research and Development (R&D): R&D expenses increased by 139% to $4.3 million (net of grants) from $1.8 million. This increase is primarily driven by costs associated with the Phase III clinical trial of prGCD, which commenced in the third quarter of 2007.
- Financial Income: Financial income increased to $1.2 million from $331,000, attributed to higher cash balances from the October 2007 public offering and the devaluation of the U.S. Dollar against the New Israeli Shekel (NIS).
- Liquidity: Cash and cash equivalents decreased by approximately $4.0 million during the quarter to $57.8 million, despite the strong cash position established by the October 2007 offering.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash resources are sufficient to fund operations for at least the next 24 months. The Company expects to continue incurring substantial operating losses as it advances clinical trials and expands its infrastructure.
- Future Funding: The Company anticipates needing additional funds for the commercialization of prGCD and further development of its pipeline. Future financing may come from public/private equity offerings, debt, or collaborations, which could result in shareholder dilution.
- Key Risks:
- Regulatory Approval: Success is dependent on FDA and foreign regulatory approvals, which are not guaranteed.
- Clinical Trial Risks: Delays in patient enrollment or negative trial results could materially impact the business.
- Capital Requirements: Inability to secure additional financing could force the Company to delay or reduce R&D programs.
- Currency Fluctuation: Approximately 35% of costs are incurred in NIS; a decline in the USD value relative to the NIS increases operational costs.
- Unusual Items: The filing notes a cumulative effect of a change in accounting principle of $(37,000) impacting the net loss. Share-based compensation was significant, totaling $2.2 million for the quarter.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $57.8 million cash balance against the projected 24-month burn rate, considering potential acceleration of clinical trial costs.
- Phase III Trial Progress: Confirm the status of patient enrollment and interim data for the prGCD Phase III trial, as this is the primary driver of R&D expenses and future valuation.
- Grant Dependency: Assess the reliability of the $1.4 million in grants received from the Office of the Chief Scientist (OCS) and the timing of future grant receivables.
- Dilution Risk: Review the outstanding options and warrants (approximately 10.6 million shares excluded from diluted EPS) and the potential impact of future equity raises.
- Currency Exposure: Monitor the USD/NIS exchange rate, as fluctuations directly impact the Company's operating expenses and financial income.